TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression

Tumor Biology

Volumn 34, Issue 6, 2013, Pages 3839-3851

  Bjerre, Christina ^a,b   Vinther, Lena ^a,b   Belling, Kirstine C ^b,c   Würtz, Sidse Ø ^a   Yadav, Rachita ^b,c   Lademann, Ulrik ^a,b   Rigina, Olga ^b,c   Do, Khoa Nguyen ^c   Ditzel, Henrik J ^b,d,e   Lykkesfeldt, Anne E ^f   Wang, Jun ^b,g   Nielsen, Henrik Bjørn ^c   Brünner, Nils ^a,b   Gupta, Ramneek ^b,c   Schrohl, Anne Sofie ^a,b   Stenvang, Jan ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Sino Danish Breast Cancer Research Centre   (Denmark)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

^f DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^g BGI SHENZHEN   (China)

Author keywords

Fulvestrant resistance; Gene expression; MCF 7 breast cancer cells; Progesterone receptor; TIMP1; Western blotting

Indexed keywords

AFIMOXIFENE; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; PROGESTERONE RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; METABOLISM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TIMP1 GENE;

EID: 84891484408     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0969-7     Document Type: Article

References (53)

1. Nawaz Z, Stancel GM, Hyder SM. The pure antiestrogen ICI 182,780 inhibits progestin-induced transcription. Cancer Res. 1999;59:372-6.
2. Rosenberg Zand RS, Grass L, Magklara A, Jenkins DJ, Diamandis EP. Is ICI 182,780 an antiprogestin in addition to being an antiestrogen? Breast Cancer Res Treat. 2000;60:1-8.
3. Hyder SM, Stancel GM. Inhibition of progesterone-induced VEGF production in human breast cancer cells by the pure antiestrogen ICI 182,780. Cancer Lett. 2002;181:47-53.
4. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771-84.
5. Zilli M, Grassadonia A, Tinari N, Di GA, Gildetti S, Giampietro J, et al. Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer. Biochim Biophys Acta. 2009;1795:62-81.
6. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233-47.
7. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002;2:101-12.
8. Wurtz SO, Schrohl AS, Sorensen NM, Lademann U, Christensen IJ, Mouridsen H, et al. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer. 2005;12:215-27.
9. Wurtz SO, Schrohl AS, Mouridsen H, Brunner N. TIMP-1 as a tumor marker in breast cancer - an update. Acta Oncol. 2008;47:580-90.
10. Jung KK, Liu XW, Chirco R, Fridman R, Kim HR. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J. 2006;25:3934-42.
11. Fu ZY, Lv JH, Ma CY, Yang DP, Wang T. Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/NF-small ka, CyrillicB pathway. Biomed Pharmacother. 2011;65:163-7.
12. Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res. 2004;10:2289-98.
13. Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002;21:2245-52.
14. Willemoe GL, Hertel PB, Bartels A, Jensen MB, Balslev E, Rasmussen BB, et al. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n = 647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study. Eur J Cancer. 2009;45:2528-36.
15. Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT, et al. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res. 2006;12:7054-8.
16. Klintman M, Ornbjerg WS, Christensen IJ, Braemer HP, Ferno M, Malmberg M, et al. Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer. Breast Cancer Res Treat. 2010;121:365-71.
17. Lipton A, Ali SM, Leitzel K, Demers L, Evans DB, Hamer P, et al. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer. 2007;109:1933-9.
18. Lipton A, Leitzel K, Chaudri-Ross HA, Evans DB, Ali SM, Demers L, et al. Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer. J Clin Oncol. 2008;26:2653-8.
19. Bjerre C, Knoop A, Bjerre K, Larsen MS, Henriksen KL, Lyng MB, et al. Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer. Acta Oncol. 2013;52:82-90.
20. Neri A, Megha T, Bettarini F, Tacchini D, Mastrogiulio MG, Marrelli D, et al. Is tissue inhibitor of metalloproteinase-1 a new prognosticator for breast cancer? An analysis of 266 cases. Hum Pathol. 2012;43:1184-91.
21. Jaattela M, Benedict M, Tewari M, Shayman JA, Dixit VM. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene. 1995;10:2297-305.
22. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer. 1999;80:495-503.
23. Lundholt BK, Briand P, Lykkesfeldt AE. Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat. 2001;67:199-214.
24. Sorensen IV, Fenger C, Winther H, Foged NT, Lademann U, Brunner N, et al. Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem. 2006;54:1075-86.
25. Smyth GK. Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and computational biology solutions using R and Bioconductor. New York: Springer; 2005. p. 397-420.
26. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80.
27. Smyth GK, Speed T. Normalization of cDNA microarray data. Methods. 2003;31:265-73.
28. Wilkinson GR, Rogers CE. Symbolic descriptions of factorial models for analysis of variance. Applied Statistics. 1973;22:392-9.
29. Chambers JM. Linear models. In: Chambers JM, Hastie TJ, editors. Statistical models in S. Pacific Grove: Wadsworth & Brooks/Cole; 1992. p. 95-144.
30. Ochsner SA, Steffen DL, Hilsenbeck SG, Chen ES, Watkins C, McKenna NJ. GEMS (Gene Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17beta-estradiol in MCF-7 cells. Cancer Res. 2009;69:23-6.
31. Lage K, Karlberg EO, Storling ZM, Olason PI, Pedersen AG, Rigina O, et al. A human phenome-interactome network of protein complexes implicated in genetic disorders. Nat Biotechnol. 2007;25:309-16.
32. Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L, et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res. 2011;39:D691-7.
33. Kandasamy K, Mohan SS, Raju R, Keerthikumar S, Kumar GS, Venugopal AK, et al. NetPath: a public resource of curated signal transduction pathways. Genome Biol. 2010;11:R3.
34. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012;40:D109-14.
35. Latendresse M, Paley S, Karp PD. Browsing metabolic and regulatory networks with BioCyc. Methods Mol Biol. 2012;804:197-216.
36. Davis AP, Murphy CG, Saraceni-Richards CA, Rosenstein MC, Wiegers TC, Mattingly CJ. Comparative Toxicogenomics Database: a knowledgebase and discovery tool for chemical-gene-disease networks. Nucleic Acids Res. 2009;37:D786-92.
37. Lykkesfeldt AE, Larsen SS, Briand P. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer. 1995;61:529-34.
38. Lapidus RG, Ferguson AT, Ottaviano YL, Parl FF, Smith HS, Weitzman SA, et al. Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res. 1996;2:805-10.
39. Pathiraja TN, Shetty PB, Jelinek J, He R, Hartmaier R, Margossian AL, et al. Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients. Clin Cancer Res. 2011;17:4177-86.
40. Long X, Nephew KP. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha. J Biol Chem. 2006;281:9607-15.
41. Seo HS, Larsimont D, Querton G, El KA, Laios I, Legros N, et al. Estrogenic and anti-estrogenic regulation of estrogen receptor in MCF-7 breast-cancer cells: comparison of immunocytochemical data with biochemical measurements. Int J Cancer. 1998;78:760-5.
42. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst. 2003;95:1597-608.
43. Krell J, Januszewski A, Yan K, Palmieri C. Role of fulvestrant in the management of postmenopausal breast cancer. Expert Rev Anticancer Ther. 2011;11:1641-52.
44. Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Mader RM, Gnant M, et al. Her2 and progesterone receptor status are not predictive of response to fulvestrant treatment. Clin Cancer Res. 2007;13:4435-9.
45. Di LA, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28:4594-600.
46. Ohno S, Rai Y, Iwata H, Yamamoto N, Yoshida M, Iwase H, et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol. 2010;21:2342-7.
47. Pritchard KI, Rolski J, Papai Z, Mauriac L, Cardoso F, Chang J, et al. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat. 2010;123:453-61.
48. Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27:4530-5.
49. Bigelow RL, Williams BJ, Carroll JL, Daves LK, Cardelli JA. TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro. Breast Cancer Res Treat. 2009;117:31-44.
50. Petz LN, Ziegler YS, Schultz JR, Nardulli AM. Fos and Jun inhibit estrogen-induced transcription of the human progesterone receptor gene through an activator protein-1 site. Mol Endocrinol. 2004;18:521-32.
51. Wang MM, Traystman RJ, Hurn PD, Liu T. Non-classical regulation of estrogen receptor-alpha by ICI182,780. J Steroid Biochem Mol Biol. 2004;92:51-62.
52. Jakacka M, Ito M, Weiss J, Chien PY, Gehm BD, Jameson JL. Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J Biol Chem. 2001;276:13615-21.
53. McDevitt MA, Glidewell-Kenney C, Jimenez MA, Ahearn PC, Weiss J, Jameson JL, et al. New insights into the classical and non-classical actions of estrogen: evidence from estrogen receptor knock-out and knock-in mice. Mol Cell Endocrinol. 2008;290:24-30.